{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=OCR",
    "query": {
      "intervention": "OCR"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=OCR&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T04:20:51.526Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06121349",
      "title": "WOE of Anti-CD20 Therapies",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "ocrelizumab",
          "type": "DRUG"
        },
        {
          "name": "ofatumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "21 Years to 85 Years"
      },
      "enrollment_count": 157,
      "start_date": "2023-12-04",
      "completion_date": "2025-06-13",
      "has_results": false,
      "last_update_posted_date": "2025-07-11",
      "last_synced_at": "2026-09-04T04:20:51.526Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06121349"
    },
    {
      "nct_id": "NCT05081700",
      "title": "A Systems Approach to Understanding Disease Processes in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "All patients in the study will be treated with ocrelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 14,
      "start_date": "2020-05-11",
      "completion_date": "2023-11-03",
      "has_results": false,
      "last_update_posted_date": "2024-10-02",
      "last_synced_at": "2026-09-04T04:20:51.526Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon • Seattle, Washington",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05081700"
    },
    {
      "nct_id": "NCT05950308",
      "title": "Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 61,
      "start_date": "2022-01-05",
      "completion_date": "2022-07-14",
      "has_results": false,
      "last_update_posted_date": "2023-07-18",
      "last_synced_at": "2026-09-04T04:20:51.526Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05950308"
    },
    {
      "nct_id": "NCT07566988",
      "title": "A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2604,
      "start_date": "2024-10-25",
      "completion_date": "2025-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-09-04T04:20:51.526Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07566988"
    },
    {
      "nct_id": "NCT05285891",
      "title": "Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ocrelizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Ocrelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 123,
      "start_date": "2023-02-07",
      "completion_date": "2032-02-25",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-09-04T04:20:51.526Z",
      "location_count": 13,
      "location_summary": "New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 10 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05285891"
    },
    {
      "nct_id": "NCT07779460",
      "title": "A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 7466,
      "start_date": "2026-04-08",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-04T04:20:51.526Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07779460"
    },
    {
      "nct_id": "NCT06831071",
      "title": "Evaluation of Hypoxia in Primary Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Pimonidazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yana Najjar",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2025-04-09",
      "completion_date": "2029-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-09-04T04:20:51.526Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06831071"
    },
    {
      "nct_id": "NCT00743509",
      "title": "A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteosarcoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide and Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2008-08",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2015-09-28",
      "last_synced_at": "2026-09-04T04:20:51.526Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00743509"
    },
    {
      "nct_id": "NCT07181811",
      "title": "Assessing the Effects of Ongoing Ocrelizumab (OCR) Therapy on Fatigue and Cognition in Veterans With Multiple Sclerosis",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Multiple Sclerosis patients who have been on Ocrelizumab will undergo cognitive and fatigue assessments",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Anza Memon",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-09-30",
      "completion_date": "2028-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-18",
      "last_synced_at": "2026-09-04T04:20:51.526Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07181811"
    },
    {
      "nct_id": "NCT02545868",
      "title": "A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "23-PPV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "13-PCV Booster",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "KLH",
          "type": "BIOLOGICAL"
        },
        {
          "name": "OCR",
          "type": "DRUG"
        },
        {
          "name": "TT Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 102,
      "start_date": "2015-10-27",
      "completion_date": "2021-09-21",
      "has_results": true,
      "last_update_posted_date": "2024-03-26",
      "last_synced_at": "2026-09-04T04:20:51.526Z",
      "location_count": 20,
      "location_summary": "Cullman, Alabama • Tucson, Arizona • Fullerton, California + 17 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02545868"
    }
  ]
}